| Literature DB >> 24424406 |
Saverio Candido1, Venerando Rapisarda2, Andrea Marconi3, Grazia Malaponte1, Valentina Bevelacqua1, Pietro Gangemi4, Aurora Scalisi5, James A McCubrey6, Roberta Maestro7, Demetrios A Spandidos8, Concettina Fenga3, Massimo Libra1.
Abstract
Sun-exposure is one of the risk factors associated with the development of a cutaneous neoplasm. In melanoma, the Ras-Raf-MEK-ERK (MAPK) signaling pathway is constitutively activated through multiple mechanisms, including B-Raf mutation. It has been hypothesized that B-Raf mutations in melanocytic lesions arise from DNA damage induced by ultraviolet (UV) radiation. However, it is still discussed if B-Raf mutations are associated with melanoma patients exposed to the sun. Therefore, in the present study, the known B-RafV600E mutation was analysed in melanoma samples from 30 indoor and 38 outdoor workers. B-RafV600E mutation was detected in 52 and 73% of outdoor workers and indoor workers, respectively. Of note, this mutation was identified in 12 of 14 (85%) melanoma of the trunk diagnosed in indoor workers and in 9 of 19 (47%) samples from outdoor workers (p=0.03). By analyzing melanomas of other body sites, no statistical difference in the frequency of B-RafV600E mutation was identified between the groups of workers. It appears that the mutation detected among indoor workers may be associated with a recreational or intermittent exposure to the sun, as usually the trunk is a sun-protected body site. Overall, these data indicate that the B-RafV600E mutation detected in melanoma is not associated with a chronic exposure to the sun. Mutations detected in other genes may also contribute to melanoma development in the subset of patients exposed to UV radiation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24424406 PMCID: PMC3926654 DOI: 10.3892/or.2014.2977
Source DB: PubMed Journal: Oncol Rep ISSN: 1021-335X Impact factor: 3.906
Clinical characteristics of melanoma patients.
| Clinical features | Outdoor (38) | Indoor (30) | P-value |
|---|---|---|---|
| Gender | |||
| Male | 34 (89) | 18 (60) | 0.004 |
| Female | 4 (11) | 12 (40) | |
| Age | |||
| ≤55 | 21 (55) | 16 (53) | NS |
| >55 | 17 (45) | 14 (47) | |
| Tumor type | |||
| Primary melanoma | 25 (66) | 18 (60) | NS |
| Metastatic melanoma | 13 (34) | 12 (40) | |
| Clark’s level | |||
| III | 13 (34) | 13 (43) | NS |
| IV | 11 (29) | 17 (57) | |
| V | 1 (3) | - | |
| Breslow thickness | |||
| ≤2.00 mm | 13 (34) | 10 (33) | NS |
| 2.01–5.00 mm | 14 (37) | 10 (33) | |
| ≥5.00 mm | 11 (29) | 10 (33) | |
| Tumor site | |||
| Trunk | 19 (50) | 14 (47) | NS |
| Head and Neck | 12 (32) | 9 (30) | |
| Limbs | 7 (18) | 7 (23) | |
Including nose and scalp. NS, not significant.
Distribution of B-RAFV600E mutation according to tumor sites in the groups of outdoor and indoor workers.
| Tumor site | Outdoor | Indoor | P-value | |
|---|---|---|---|---|
| Trunk | Yes | 9 (47) | 12 (85) | 0.03 |
| No | 10 (53) | 2 (15) | ||
| Total | 19 | 14 | ||
| Head and neck | Yes | 5 (42) | 7 (78) | 0.18 |
| No | 7 (58) | 2 (22) | ||
| Total | 12 | 9 | ||
| Limbs | Yes | 6 (86) | 3 (43) | 0.26 |
| No | 1 (14) | 4 (57) | ||
| Total | 7 | 7 | ||
| All sites | Yes | 20 (52) | 22 (73) | 0.08 |
| No | 18 (48) | 8 (27) | ||
| Total | 38 | 30 |
Fisher’s exact test, Two-tailed.
Distribution of B-RAFV600E mutation according to chronic exposure to sun and intermittent exposure to sun.a
| Chronic exposure to sun | Intermittent exposure to sun | P-value | |
|---|---|---|---|
| Yes | 9 (16) | 30 (47) | <0.0001 |
| No | 46 (84) | 34 (53) | |
| Total | 55 | 64 |
Cosmic Catalogue of Mutations in Cancer analysis;
Fisher’s exact test, Two-tailed.
Figure 1Potential mechanism of melanoma development and progression after UV-damage. UVA, Ultraviolet A; UVB, ultraviolet B; CPDs, cyclobutane pyrimidine dimers; Fapy, formamidopyrimidines; 8-oxo-dG, 8-Oxo-2′-deoxyguanosine; G^T, guanine to thymidine transversion; B-RAF, v-raf murine sarcoma viral oncogene homolog B; CDKN2A, cyclin-dependent kinase inhibitor 2A; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; PTEN, phosphatase and tensin homolog; TP53, tumor protein p53; PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α; MITF, microphthalmia-associated transcription factor; APAF-1, apoptotic peptidase activating factor 1; AKT3, v-akt murine thymoma viral oncogene homolog 3.